Quantum Surgical Secures $46.3 Million in Funding to Revolutionize Cancer Treatment Worldwide

Quantum Surgical, a pioneering French company specialized in medical robotics and artificial intelligence, is thrilled to announce the successful completion of a funding round, raising a remarkable €46.3 million. Founded in 2017 and headquartered in Montpellier, France, Quantum Surgical has made significant strides in revolutionizing cancer treatment through its innovative Epione® robotic percutaneous ablation platform. This cutting-edge technology is designed to provide curative and early interventions for cancer patients, allowing for better-targeted and less invasive treatment options. With a mission to standardize access to care, Quantum Surgical has already treated hundreds of individuals globally, making its mark as a game-changer in oncology. The newly acquired funds will be strategically allocated towards expanding research and development efforts, enhancing their product offerings, and scaling operations to meet the growing demand in the healthcare sector. In 2022, the company was honored with the Prix Galien USA, a prestigious accolade often referred to as the Nobel Prize for biopharmaceutical research, further solidifying its position as a leader in the field. Moreover, in 2023, Quantum Surgical was selected to join the French Tech 2030 program, a governmental initiative aimed at supporting emerging champions of disruptive innovation. With a dedicated team of over 110 employees and a commitment to transforming how cancer is treated, Quantum Surgical is set to play an instrumental role in the future of medical technology. This funding marks an exciting new chapter in the company’s journey as it continues to push the boundaries of possibility in cancer care.